Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-07-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.39.7646PMID 22851564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease.

  2012cited by this paper
• Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

  2011cited by this paper
• Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

  2011cited by this paper
• A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.

  2011cited by this paper
• A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer

  2010cited by this paper
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk.

  2010cited by this paper
• Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

  2010cited by this paper
• Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

  2010cited by this paper
• Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

  2010cited by this paper
• F1000 highlights

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

  2009cited by this paper
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  2009cited by this paper
• Role of RAF/MEK/ERK pathway, p‐STAT‐3 and Mcl‐1 in sorafenib activity in human pancreatic cancer cell lines

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

  2009cited by this paper
• Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

  2008cited by this paper
• A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501

  2008cited by this paper
• Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

  2007cited by this paper
• Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease.

  2007cited by this paper
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

  2003cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper

• Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

  2025cites this paper
• Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks

  2025cites this paper
• Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine

  2024cites this paper
• Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors.

  2024cites this paper
• Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Emerging Nanomedicine Approaches in Targeted Lung Cancer Treatment

  2024cites this paper
• Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients

  2024cites this paper
• Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells

  2023cites this paper
• Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

  2023cites this paper
• BRAF gene as a potential target to attenuate drug resistance and treat cancer

  2023cites this paper
• Gossypol enhances the efficacy of sorafenib by trigging autophagy and apoptosis in metastatic lung cancer cells: An upshot of Chou-Talalay combination index process.

  2023cites this paper
• Escin enhanced the efficacy of sorafenib by autophagy‐mediated apoptosis in lung cancer cells

  2023cites this paper
• Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)

  2022cites this paper
• Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

  2022cites this paper
• Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer

  2022cites this paper
• The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer

  2021cites this paper
• Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

  2021cites this paper
• A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer

  2021cites this paper
• Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer

  2021cites this paper
• Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

  2021cites this paper
• The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

  2020cites this paper
• New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

  2020cites this paper
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer

  2020cites this paper
• A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

  2020cites this paper
• Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms

  2020cites this paper
• Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients.

  2020cites this paper
• Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

  2020cites this paper
• Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small – Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

  2019cites this paper
• A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC

  2019cites this paper
• Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors

  2019cites this paper
• Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small – Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

  2019cites this paper
• Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution.

  2019cites this paper
• Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas

  2019cites this paper
• VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review

  2019cites this paper
• Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer

  2019cites this paper
• Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

  2019cites this paper
• Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer

  2019cites this paper
• Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

  2019cites this paper
• Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

  2019cites this paper
• Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.

  2019cites this paper
• Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

  2019cites this paper
• Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non–Small Cell Lung Cancer

  2019cites this paper
• Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

  2018cites this paper
• Understanding shared pathogenesis between chronic obstructive pulmonary disease (COPD) and lung cancer by means of cell specific genomics

  2018cites this paper
• Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis

  2018cites this paper
• Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

  2018cites this paper
• Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials

  2018cites this paper
• Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer

  2018cites this paper
• Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

  2018cites this paper
• Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations

  2018cites this paper
• Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer

  2018cites this paper
• Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint

  2018cites this paper
• Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.

  2018cites this paper
• Antiangiogenic therapies in non-small-cell lung cancer.

  2018cites this paper
• A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors

  2018cites this paper
• Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.

  2018cites this paper
• Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients

  2018cites this paper
• Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.

  2018cites this paper
• Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.

  2018cites this paper
• Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

  2017cites this paper
• Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review

  2017cites this paper
• Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition.

  2017cites this paper
• Respuesta al tratamiento oncoespecífico en carcinomas no microcíticos etapa IIIA no quirúrgica

  2017cites this paper
• Strategies targeting angiogenesis in advanced non-small cell lung cancer

  2017influential citation
• Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

  2017cites this paper
• Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

  2017cites this paper
• Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients

  2017cites this paper
• Antiangiogenic Therapy in Advanced Non–small‐cell Lung Cancer: A Meta‐analysis of Phase III Randomized Trials

  2017cites this paper
• Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.

  2017cites this paper
• Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.

  2017influential citation
• Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine

  2017cites this paper
• Tumor angiogenesis revisited: Regulators and clinical implications

  2017cites this paper
• The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

  2017cites this paper
• Bevacizumab in advanced lung cancer: state of the art.

  2017cites this paper
• Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.

  2017cites this paper
• Angiogenesis Inhibitors in NSCLC

  2017cites this paper
• Enhancement of Antiangiogenic Efficacy of Iron(II) Complex by Selenium Substitution.

  2017cites this paper
• Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea

  2016cites this paper
• Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

  2016cites this paper
• VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside

  2016cites this paper
• Anti-angiogenesis in Personalized Therapy of Lung Cancer.

  2016cites this paper
• Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.

  2016cites this paper
• Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

  2016cites this paper
• The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

  2016cites this paper
• Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?

  2016cites this paper
• Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.

  2016cites this paper
• Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials

  2016cites this paper
• Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

  2016cites this paper
• Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer

  2016cites this paper
• Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

  2016cites this paper
• Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

  2016cites this paper
• International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes

  2016cites this paper
• Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

  2016cites this paper
• Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†

  2016cites this paper
• Nintedanib in NSCLC: evidence to date and place in therapy

  2016cites this paper
• Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer

  2016cites this paper
• Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients

  2016cites this paper
• The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

  2016cites this paper
• Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review

  2016cites this paper
• Metastatic Lung Cancer: Emerging Therapeutic Strategies

  2016cites this paper